Your browser doesn't support javascript.
loading
Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).
Lovato, Evellyn Claudia Wietzikoski; Barboza, Lorena Neris; Wietzikoski, Samantha; de Souza, Amanda Nascimento Vasques; Auth, Pablo Alvarez; Junior, Arquimedes Gasparotto; Dos Reis Lívero, Francislaine Aparecida.
Afiliação
  • Lovato ECW; Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.
  • Barboza LN; Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.
  • Wietzikoski S; Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.
  • de Souza ANV; Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.
  • Auth PA; Laboratory of Preclinical Research of Natural Products, Post- Graduate Program in Animal Science with Emphasis on Bioactive Products, Paranaense University, Umuarama, PR, Brazil.
  • Junior AG; Laboratory of Electrophysiology and Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, MS, Brazil.
  • Dos Reis Lívero FA; Laboratory of Preclinical Research of Natural Products, Post-Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, PR, Brazil.
Curr Pharm Des ; 27(1): 115-126, 2021.
Article em En | MEDLINE | ID: mdl-32634080
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), termed coronavirus disease 2019 (COVID-19) by the World Health Organization, is a newly emerging zoonotic agent that emerged in China in December 2019. No specific treatment for COVID-19 is currently available. Usual palliative treatment includes maintaining hydration and nutrition and controlling fever and cough. The clinical severity and extent of transmission need to be determined, and therapeutic options need to be developed and optimized. METHODS: The present review discusses the recent repurposing of drugs for COVID-19 treatment. RESULTS: Several compounds, including remdesivir, lopinavir, ritonavir, interferon-ß, ribavirin, chloroquine/ hydroxychloroquine, azithromycin, tocilizumab, and ivermectin, have emerged as promising alternatives. They block the virus from entering host cells, prevent viral replication, and attenuate exacerbation of the host's immune response. CONCLUSION: Although some evidence indicates the positive actions of different classes of compounds for the treatment of COVID-19, few clinical assays have been established to definitively demonstrate their therapeutic value in humans. Multicenter clinical studies are urgently needed to validate and standardize therapeutic regimens that involve these agents. Although science has not yet presented us with a specific drug against COVID-19, the repurposing of drugs appears to be promising in our fight against this devastating disease.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Preparações Farmacêuticas / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Curr Pharm Des Assunto da revista: FARMACIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Emirados Árabes Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Preparações Farmacêuticas / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Curr Pharm Des Assunto da revista: FARMACIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Emirados Árabes Unidos